Artelo Biosciences, Inc. financial data

Symbol
ARTL on Nasdaq, ATLEW on OTC
Industry
Pharmaceutical Preparations
Location
505 Lomas Santa Fe, Suite 160, Solana Beach, CA
State of incorporation
NV
Fiscal year end
December 31
Former names
REACTIVE MEDICAL INC. (to 4/17/2017), KNIGHT KNOX DEVELOPMENT CORP. (to 2/6/2017)
Latest financial report
10-Q - Q3 2024 - Nov 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 831 % -55.7%
Debt-to-equity 11.2 % +124%
Return On Equity -104 % -85.4%
Return On Assets -93.9 % -75.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 3.23M shares +1.22%
Common Stock, Shares, Outstanding 3.23M shares +2.07%
Entity Public Float 5.63M USD -58.9%
Common Stock, Value, Issued 3K USD 0%
Weighted Average Number of Shares Outstanding, Diluted 3.23M shares +9.46%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 5.64M USD +6.47%
General and Administrative Expense 3.9M USD -20%
Operating Income (Loss) -9.54M USD +6.2%
Nonoperating Income (Expense) 415K USD -32.1%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -9.12M USD +4.54%
Earnings Per Share, Diluted -0.35 USD/shares +57.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 2.64M USD -63%
Marketable Securities, Current 500K USD -95.1%
Assets, Current 4.99M USD -62.9%
Operating Lease, Right-of-Use Asset 108K USD +272%
Intangible Assets, Net (Excluding Goodwill) 2.04M USD 0%
Other Assets, Noncurrent 3K USD
Assets 7.14M USD -54%
Liabilities, Current 697K USD -24.3%
Operating Lease, Liability, Noncurrent 78K USD
Liabilities 775K USD -15.9%
Accumulated Other Comprehensive Income (Loss), Net of Tax -218K USD -9.55%
Retained Earnings (Accumulated Deficit) -46.4M USD -24.5%
Stockholders' Equity Attributable to Parent 6.36M USD -56.4%
Liabilities and Equity 7.14M USD -54%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -2.94M USD -34.6%
Net Cash Provided by (Used in) Financing Activities 55K USD
Net Cash Provided by (Used in) Investing Activities 1.27M USD -42.3%
Common Stock, Shares Authorized 50M shares 0%
Common Stock, Shares, Issued 3.23M shares +2.07%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.62M USD -5886%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 4.36M USD +65.1%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD
Deferred Tax Assets, Valuation Allowance 5.14M USD +18.4%
Operating Lease, Liability 87K USD +1350%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -9.14M USD +2.41%
Operating Lease, Liability, Current 34K USD +6.25%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 417K shares 0%
Additional Paid in Capital 52.9M USD +1.78%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Interest Expense 0 USD -100%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%